TG Therapeutics Inc (TGTX) - Total Assets
Based on the latest financial reports, TG Therapeutics Inc (TGTX) holds total assets worth $1.53 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check TG Therapeutics Inc (TGTX) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
TG Therapeutics Inc - Total Assets Trend (1996–2025)
This chart illustrates how TG Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Explore investment intensity of TG Therapeutics Inc to see how much of total assets are deployed in long-term investments.
TG Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
TG Therapeutics Inc's total assets of $1.53 Billion consist of 59.3% current assets and 40.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.4% |
| Accounts Receivable | $305.63 Million | 28.7% |
| Inventory | $125.59 Million | 11.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1996–2025)
This chart illustrates how TG Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see TGTX market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TG Therapeutics Inc's current assets represent 59.3% of total assets in 2025, a decrease from 95.8% in 1996.
- Cash Position: Cash and equivalents constituted 7.4% of total assets in 2025, down from 95.8% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1996.
- Asset Diversification: The largest asset category is accounts receivable at 28.7% of total assets.
TG Therapeutics Inc Competitors by Total Assets
Key competitors of TG Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
TG Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.81 | 4.02 | 5.20 |
| Quick Ratio | 5.12 | 3.04 | 5.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $899.86 Million | $484.30 Million | $367.52 Million |
TG Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between TG Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.53 |
| Latest Market Cap to Assets Ratio | 5.90 |
| Asset Growth Rate (YoY) | 84.1% |
| Total Assets | $1.06 Billion |
| Market Capitalization | $6.27 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values TG Therapeutics Inc's assets at a significant premium (5.90x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: TG Therapeutics Inc's assets grew by 84.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for TG Therapeutics Inc (1996–2025)
The table below shows the annual total assets of TG Therapeutics Inc from 1996 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.06 Billion | +84.05% |
| 2024-12-31 | $577.69 Million | +75.28% |
| 2023-12-31 | $329.59 Million | +70.27% |
| 2022-12-31 | $193.57 Million | -49.01% |
| 2021-12-31 | $379.63 Million | -39.32% |
| 2020-12-31 | $625.64 Million | +283.80% |
| 2019-12-31 | $163.01 Million | +94.96% |
| 2018-12-31 | $83.62 Million | -14.14% |
| 2017-12-31 | $97.38 Million | +77.76% |
| 2016-12-31 | $54.78 Million | -51.72% |
| 2015-12-31 | $113.47 Million | +30.81% |
| 2014-12-31 | $86.75 Million | +80.30% |
| 2013-12-31 | $48.11 Million | +117.96% |
| 2012-12-31 | $22.07 Million | +38.77% |
| 2011-12-31 | $15.91 Million | -14.64% |
| 2010-12-31 | $18.64 Million | +4996.41% |
| 2009-12-31 | $365.66K | -70.72% |
| 2008-12-31 | $1.25 Million | +27.37% |
| 2007-12-31 | $980.58K | -71.56% |
| 2006-12-31 | $3.45 Million | -69.23% |
| 2005-12-31 | $11.21 Million | +98.36% |
| 2004-12-31 | $5.65 Million | -27.56% |
| 2003-12-31 | $7.80 Million | +3010.37% |
| 2002-12-31 | $250.74K | -85.74% |
| 2001-12-31 | $1.76 Million | -44.65% |
| 2000-12-31 | $3.18 Million | -20.59% |
| 1999-12-31 | $4.00 Million | -38.46% |
| 1998-12-31 | $6.50 Million | -26.14% |
| 1997-12-31 | $8.80 Million | +266.67% |
| 1996-12-31 | $2.40 Million | -- |
About TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolat… Read more